Kyver­na lands $319M IPO as au­toim­mune CAR-T field has its mo­ment in the sun

Cal­i­for­nia biotech Kyver­na Ther­a­peu­tics will gar­ner $319 mil­lion from its Thurs­day morn­ing Nas­daq de­but as it rides a small but wel­come wave of in­vestor en­thu­si­asm for ini­tial pub­lic of­fer­ings.

The mid-stage cell ther­a­py mak­er priced at $22 apiece, sell­ing 14.5 mil­lion shares $KYTX at a val­u­a­tion of about $898 mil­lion.

Per­haps in a sign of in­vestor ap­petite for Kyver­na’s work to bring CAR-T cell ther­a­pies in­to the au­toim­mune world, be­yond their ini­tial prov­ing ground in blood can­cer, the biotech was able to haul in a larg­er chunk of cap­i­tal than it orig­i­nal­ly ex­pect­ed. Last week, the com­pa­ny set out to raise about $182 mil­lion but quick­ly broad­ened that ask to $272 mil­lion on Tues­day. Kyver­na orig­i­nal­ly sought a price range of $17 to $19 last week but upped it to $20 to $21 ear­li­er this week. It went even high­er for the fi­nal pric­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA